Insulin Resistance and Lipid Accumulation Product in Correlation to Body Mass Index in Women with Polycystic Ovary Syndrome

Godinjak, Amina; Godinjak, Zulfo; Burekovic, Azra; Surkovic, Ismana; Dizdarevic-Bostandzic, Amela; Velija-Asimi, Zelija
December 2012
Medical Archives / Medicinski Arhiv;2012, Vol. 66 Issue 6, p409
Academic Journal
Introduction: Women with Polycystic Ovary Syndrome (PCOS) are at increased risk for cardiovascular morbidity and metabolic disorders including: dyslipidaemia, hypertension, insulin resistance, gestational diabetes, type 2 diabetes, systemic inflammation and endothelial dysfunction. The prevalence of obesity and insulin resistance in women with PCOS is significantly higher compared to the general population. Lipid accumulation product is a new, cheap and easily available predictor for metabolic syndrome both in general population and in women with PCOS. Materials and methods: The study included 50 patients at the Clinic of Endocrinology, Diabetes and Metabolic Disorders, Clinical Center University of Sarajevo. All patients were diagnosed with PCOS according to the Rotterdam ESHRE criteria and were divided into two groups according to their body mass index (BMI). A prospective study established the following parameters: anthropometric measurements (waist circumference, height, weight), BMI, and serum triglycerides and insulin resistance. LAP was calculated using the formula: LAP (women) = [waist circumference (cm)-58] x [triglycerides (mmol/L)]. Results: Waist circumference in women with BMI ≤ 24.9 kg/m2 was 31 cm lower than waist circumference in women with a BMI > 25 kg/m2. Mean triglyceride value of the patients in group BMI ≤ 24.9 kg/m2 was 1.15 mmol/l lower than the mean value of triglycerides in women with a BMI >25 kg/m2. Insulin resistance was present in 66.7% in group with BMI ≤ 24.9 kg/m2, and in 75.0% in the group with BMI>25.0 kg/m2. LAP was shown to be a marker for the differentiation of insulin--resistant and nonresistant patients with a cut-off value of 17.91. Conclusion: Patients with PCOS and BMI ≤ 24.9 kg/m2 were significantly different from those with BMI>25 kg/m2 in the values of body weight, waist circumference and triglycerides. There was no statistically significant difference in insulin resistance. LAP values were higher in patients in the group with BMI > 25 kg/m2. LAP was a marker for differentiation of insulin -- resistant and non-resistant women with PCOS.


Related Articles

  • Metformin Aids Weight Loss and Metabolic Parameters Following Rimonabant Therapy.  // Fertility Weekly;3/2/2009, p3 

    The article reports on the study in Great Britain regarding how metformin helps obese polycystic ovary syndrome (PCOS) patients achieve weight loss and metabolic parameters following rimonabant therapy. It states that rimonabant and metformin are used to improve insulin resistance and...

  • Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Yildizhan, Recep; Kurdoglu, Mertihan; Adali, Ertan; Kolusari, Ali; Yildizhan, Begum; Sahin, Hanim; Kamaci, Mansur; Sahin, Hanim Guler // Archives of Gynecology & Obstetrics;Oct2009, Vol. 280 Issue 4, p559 

    Purpose: To investigate the correlation between serum 25-hydroxyvitamin D (25-OH-VD) concentrations and metabolic parameters in obese and non-obese women with polycystic ovary syndrome (PCOS).Methods: One hundred women with PCOS were divided into two groups, obese and...

  • Large effects on body mass index and insulin resistance of fat mass and obesity associated gene variants in patients with polycystic (FTO) ovary syndrome (PCOS). Tan, Susanne; Scherag, André; Janssen, Onno Eilard; Hahn, Susanne; Lahner, Harald; Dietz, Tiina; Scherag, Susann; Grallert, Harald; Vogel, Carla Ivane Ganz; Kimmig, Rainer; Illig, Thomas; Mann, Klaus; Hebebrand, Johannes; Hinney, Anke // BMC Medical Genetics;2010, Vol. 11, Special section p1 

    Background: The polycystic ovary syndrome (PCOS), a common endocrine disorder in women of child-bearing age, mainly characterised by chronic anovulation and hyperandrogenism, is often associated with insulin resistance (IR) and obesity. Its etiology and the role of IR and obesity in PCOS are not...

  • Efficacy of 2-hour post glucose insulin levels in predicting insulin resistance in polycystic ovarian syndrome with infertility. Saxena, Pikee; Prakash, Anupam; Nigam, Aruna // Journal of Human Reproductive Sciences;Jan-Apr2011, Vol. 4 Issue 1, p20 

    BACKGROUND: Insulin resistance (IR) is central to the pathogenesis of polycystic ovarian syndrome (PCOS), but tests for determining IR are elaborate, tedious and expensive. AIMS: To evaluate if "2-hour post-glucose insulin level" is an effective indicator of IR and can aid in diagnosing IR in...

  • Age and Body Mass Related Changes of Cardiovascular Risk Factors in Women With Polycystic Ovary Syndrome. Macut, Ðuro; Micić, Dragan; Parapid, Biljana; Cvijović, Goran; Šumarac, Mirjana; Kendereški, Aleksandra; Milić, Nataša; Tulić, Lidija; Muharemagić, Azra; Zorić, Svetlana; Pejković, Danica // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov/Dec2002, Vol. 59 Issue 6, p593 

    Polycystic ovary syndrome (PCOS) is considered a metabolic disorder closely related to obesity, insulin resistance (IR), hyperinsulinemia and unfavorable lipid profile, all increasing the risk for the occurrence of cardiovascular diseases. The aim of this study was to assess age and body mass...

  • Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. Aghahosseini, Marzieh; Aleyaseen, Ashraf; Safdarian, Leli; Moddaress-Hashemi, Shahab; Mofid, Behshad; Kashani, Ladan // Archives of Gynecology & Obstetrics;Dec2010, Vol. 282 Issue 6, p691 

    Purpose: The objective of this study was to assess the efficacy and safety of metformin at the dosage of 2,500 mg/day in the treatment of obese women with PCOS and also to evaluate its effect on weight, hormones, and lipid profile. Method: This study was a 4-month open-label clinical trial....

  • Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. D. Wiltgen; I.G. Benedetto; L.S. Mastella; P.M. Spritzer // Human Reproduction;Jul2009, Vol. 24 Issue 7, p1726 

    BACKGROUND Metabolic disturbances are common features of polycystic ovary syndrome (PCOS), which possibly enhance the risk of cardiovascular disease. The aim of this study was to assess the accuracy of lipid accumulation product (LAP) index as a marker of cardiovascular risk in PCOS patients. ...

  • Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome. Sam, Susan; Scoccia, Bert; Yalamanchi, Sudha; Mazzone, Theodore // Human Reproduction;Jun2015, Vol. 30 Issue 6, p1358 

    STUDY QUESTION: Are certain ethnic groups with polycystic ovary syndrome (PCOS) at increased risk of metabolic disorders? SUMMARY ANSWER: Obese Hispanic women with PCOS are at increased risk of metabolic disorders compared with age-and BMI-matched obese non-Hispanic white women with PCOS in the...

  • Polikistik over sendromunda kardiyovasküler hastalık risk faktörü olarak C-reaktif protein düzeyi ve obezite. Uludağ, Eda Ülkü; Gözükara, İlay; Kucur, Suna Kabil; Keskin, Havva; Kılıç, Halime; Kamalak, Zeynep; Kargılı, Ayşe; Durmaz, Şenay Arıkan // Dicle Medical Journal / Dicle Tip Dergisi;2013, Vol. 40 Issue 3, p426 

    Objective: To investigate the role of C-reactive protein (CRP) level elevation and obesity for the increased cardiovascular disease risk in polycystic ovary syndrome (PCOS). Methods: A hundred and nine patients with PCOS and 30 age matched healthy volunteers with regular menstrual cycle are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics